bpc-157 not approved by fda statement fda.gov Undercutting HHS Secretary Robert F. Kennedy Jr.'s BPC-157: The Real Reason Why

TB-500 provides critical enhancement of cellular migration and epithelial coverage that drives wound closure, with research demonstrating that topical or intraperitoneal TB-500 administration increases reepithelialization by 42% over controls at 4 days post-wounding and 61% at 7 days, with treated wounds showing enhanced contraction (at least 11% more than controls by day 7) and superior architectural organization

U100 means 100 units per milliliter (ml)

Fujikura Speeder NX TCS

TB-500 reproduces the active region of that protein in a more stable synthetic form

Senescent Endothelial Cell Elimination & Vascular Ageing (Frontiers in Bioengineering, 2025/2026) p53/BCL-2/Caspase-3 Pathway Activation Selectively Clears Senescent Endothelial Cells A study published in Frontiers in Bioengineering and Biotechnology investigated the mechanism by which FOXO4-DRI induces apoptosis in senescent endothelial cells